<DOC>
	<DOCNO>NCT00004654</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate migraine prophylaxis soy protein isolate patient hereditary hemorrhagic telangiectasia . II . Assess whether soy protein isolate reduces frequency severity epistaxis gastrointestinal bleeding patient .</brief_summary>
	<brief_title>Phase III Randomized , Placebo-Controlled , Crossover Study Soy Protein Isolate Hereditary Hemorrhagic Telangiectasia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize study . One group patient treat soy protein isolate 12 week . The control group receive placebo 12 week . Patients cross alternate group follow 4-week washout .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<criteria>Hereditary hemorrhagic telangiectasia ( HHT ) 2 follow : Firstdegree relative HHT History recurrent epistaxis gastrointestinal bleeding Three skin telangiectasia Migraine headache meeting International Headache Society criteria 3 time month 1 year No pattern daily headaches No severe head trauma No onset headaches 50 year age At least 1 month since migraine prophylaxis At least 1 month since follow medication : Beta blocker ; Calcium channel blocker ; Divalproex sodium ; Tricyclic antidepressant ; Selective serotonin reuptake inhibitor Concurrent regular treatment migraine gastrointestinal hemorrhage allow Creatinine great 2.5 g/dL No allergy soy No pregnant woman No woman intent become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>hereditary hemorrhagic telangiectasia</keyword>
	<keyword>rare disease</keyword>
</DOC>